CELLECT BIOTECH/S (APOP) Hits New 52-Week Low at $1.00

CELLECT BIOTECH/S (NASDAQ:APOP) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $1.00 and last traded at $1.02, with a volume of 177942 shares. The stock had previously closed at $1.05.

Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Thursday, January 3rd. HC Wainwright set a $12.00 target price on shares of CELLECT BIOTECH/S and gave the stock a “buy” rating in a research note on Wednesday, December 12th.

The company has a market capitalization of $5.55 million, a PE ratio of -0.70 and a beta of 2.84.

An institutional investor recently bought a new position in CELLECT BIOTECH/S stock. Susquehanna International Group Ltd. acquired a new stake in CELLECT BIOTECH/S (NASDAQ:APOP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,964 shares of the company’s stock, valued at approximately $25,000. CELLECT BIOTECH/S accounts for about 0.0% of Susquehanna International Group Ltd.’s holdings, making the stock its 28th largest position. Susquehanna International Group Ltd. owned approximately 0.22% of CELLECT BIOTECH/S at the end of the most recent quarter. 2.85% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2019/02/18/cellect-biotech-s-apop-hits-new-52-week-low-at-1-00.html.


Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Read More: Why is cost of goods sold important?

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit